<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>FORTIS</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">FORTIS</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="fortis-healthcare-limited" class="section level1">
<h1>Fortis Healthcare Limited</h1>
<p><a href="/reports01/index/industry/rp-Hospital.html">Hospital</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.FORTIS.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="fortis-healthcare-limited-business-and-investment-summary-november-11-2025" class="section level9">
<p class="heading"><strong>Fortis Healthcare Limited ‚Äì Business and Investment Summary (November 11, 2025)</strong></p>
<p>Fortis Healthcare, a leading integrated healthcare provider in India, has released its unaudited financial results for <strong>Q2 FY26 (ended September 30, 2025)</strong>, alongside a significant update on the completion of IHH Healthcare‚Äôs open offer acquisition. This analysis synthesizes performance, growth drivers, risks, and competitive context using the provided documents.</p>
<hr />
</div>
<div id="summary-overview" class="section level6">
<h6>üîç <strong>Summary Overview</strong></h6>
<ul>
<li><strong>Stock &amp; Listings</strong>: Listed on NSE (FORTIS) and BSE (532843), regulated under SEBI LODR.</li>
<li><strong>Recent Ownership Update</strong>: IHH Healthcare Berhad, an indirect parent, has completed open offers and now holds <strong>31.17% in Fortis</strong> and <strong>62.73% in Fortis Malar Hospitals</strong>.</li>
<li><strong>Reporting Period</strong>: Quarter and half-year ended <strong>September 30, 2025</strong>.</li>
<li><strong>Corporate Headquarters</strong>: Gurgaon, Haryana; registered in Mohali.</li>
<li><strong>Leadership</strong>: Dr.¬†Ashutosh Raghuvanshi, MD &amp; CEO.</li>
</ul>
<hr />
</div>
<div id="performance-highlights-q2-h1-fy26" class="section level6">
<h6>üìà PERFORMANCE HIGHLIGHTS ‚Äì Q2 &amp; H1 FY26</h6>
<div id="key-financial-metrics-consolidated" class="section level9">
<p class="heading">‚úÖ <strong>Key Financial Metrics (Consolidated)</strong></p>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY25</th>
<th>Q2 FY26</th>
<th>YoY Œî</th>
<th>H1 FY25</th>
<th>H1 FY26</th>
<th>YoY Œî</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Revenue (INR Cr)</td>
<td>1,988</td>
<td>2,331</td>
<td><strong>+17.3%</strong></td>
<td>3,847</td>
<td>4,498</td>
<td><strong>+16.9%</strong></td>
</tr>
<tr class="even">
<td>Operating EBITDA</td>
<td>435</td>
<td>556</td>
<td><strong>+28.0%</strong></td>
<td>777</td>
<td>1,047</td>
<td><strong>+34.7%</strong></td>
</tr>
<tr class="odd">
<td>EBITDA Margin</td>
<td>21.9%</td>
<td><strong>23.9%</strong></td>
<td>+200 bps</td>
<td>20.2%</td>
<td><strong>23.3%</strong></td>
<td>+310 bps</td>
</tr>
<tr class="even">
<td>PAT</td>
<td>193</td>
<td>329</td>
<td><strong>+70.3%</strong></td>
<td>367</td>
<td>596</td>
<td><strong>+62.3%</strong></td>
</tr>
<tr class="odd">
<td>EPS (INR)</td>
<td>2.34</td>
<td>4.26</td>
<td>‚Äî</td>
<td>4.54</td>
<td>7.71</td>
<td>‚Äî</td>
</tr>
</tbody>
</table>
<blockquote>
<p>‚ö†Ô∏è <strong>Note</strong>: PAT includes <strong>exceptional gains (INR 23.5 Cr Q2, INR 36.2 Cr H1)</strong> due to <strong>reversal of impairment in an associate</strong>, contrasted with <strong>exceptional losses (INR 59.8 Cr Q2 FY25)</strong>.</p>
</blockquote>
<hr />
</div>
</div>
<div id="segmental-performance" class="section level6">
<h6>üè• SEGMENTAL PERFORMANCE</h6>
<div id="hospital-business-core-driver" class="section level9">
<p class="heading">1. <strong>Hospital Business (Core Driver)</strong></p>
<ul>
<li><strong>Revenue</strong>: INR 1,974 Cr (Q2 FY26) ‚ûù <strong>+19.3%</strong> YoY.</li>
<li><strong>EBITDA Margin</strong>: 22.9% (up from 21.4%).</li>
<li><strong>No.¬†of Operational Beds</strong>: ~5,800 (including O&amp;M), across 33 facilities.</li>
<li><strong>Occupancy Rate</strong>: 71% (stable vs 72% in Q2 FY25), but <strong>occupied beds grew 12.9%</strong> ‚ûù volume-driven growth.</li>
<li><strong>ARPOB (Revenue per Occupied Bed)</strong>: INR 2.51 Cr/year ‚ûù up from INR 2.37 Cr, driven by:
<ul>
<li>International patient revenues: <strong>+26% YoY to INR 169 Cr</strong>, accounting for <strong>8.1%</strong> of hospital revenue.</li>
<li>Rising penetration of <strong>digital channels</strong> (up 20.4% YoY; contributing 29.5% to revenue).</li>
</ul></li>
<li><strong>Specialty Growth (YoY)</strong>:
<ul>
<li><strong>Oncology</strong>: +29%</li>
<li><strong>Renal Sciences</strong>: +22%</li>
</ul></li>
<li><strong>Surgical Volume Growth</strong>:
<ul>
<li>Robotic Surgeries: <strong>+66%</strong></li>
<li>Radiation Therapy: <strong>+54%</strong></li>
</ul></li>
</ul>
<blockquote>
<p>üìå Focus: Expansion of key service lines is fueling margin improvement and premium pricing.</p>
</blockquote>
<hr />
</div>
<div id="diagnostic-business-agilus-diagnostics" class="section level9">
<p class="heading">2. <strong>Diagnostic Business (Agilus Diagnostics)</strong></p>
<ul>
<li>Acquired 31.5% PE stake (leading to consolidation).</li>
<li><strong>Gross Revenue</strong>: INR 400 Cr (+7.3% YoY); Net Revenue (interco-adjusted): INR 357.5 Cr.</li>
<li><strong>EBITDA Margin (on gross revenue)</strong>: <strong>26.1%</strong> vs 21.5% in Q2 FY25.</li>
<li><strong>Excluding one-offs</strong>, FY25 margin was 24.0% ‚Äî implying <strong>actual improvement</strong>.</li>
<li><strong>Test Volumes</strong>: 10.62 million (+2.1% YoY).</li>
<li><strong>Customer Touchpoints</strong>: Now <strong>4,330</strong> (up 200+ this quarter).</li>
<li><strong>Revenue Mix</strong>:
<ul>
<li>B2C: 52‚Äì53%</li>
<li>B2B: 47‚Äì48%</li>
<li>International: 3%</li>
</ul></li>
</ul>
<blockquote>
<p>üìà Strong EBITDA improvement reflects <strong>operational efficiencies</strong>, scale, and <strong>recovery post-rebranding</strong> costs.</p>
</blockquote>
<hr />
</div>
</div>
<div id="growth-prospects-strategic-tailwinds" class="section level6">
<h6>üöÄ GROWTH PROSPECTS &amp; STRATEGIC TAILWINDS</h6>
<div id="accelerating-physical-operational-expansion" class="section level9">
<p class="heading">1. <strong>Accelerating Physical &amp; Operational Expansion</strong></p>
<ul>
<li><strong>New Hospital Projects</strong>:
<ul>
<li><strong>Greater Noida</strong>: 200-bed facility transitioned from O&amp;M to <strong>long-term lease</strong> (15-year lease signed in Sep ‚Äô25).</li>
<li><strong>Lucknow</strong>: O&amp;M agreement for <strong>550-bed greenfield super-specialty hospital</strong>.</li>
</ul></li>
<li><strong>NCR Network Expansion</strong>: Total bed capacity in Delhi NCR now <strong>~2,100 beds</strong>.</li>
<li><strong>Bed Additions</strong>:
<ul>
<li>Jalandhar (191 beds), Greater Noida (200 beds), BG Road (20 beds).</li>
<li>Ongoing expansion: Faridabad (50 beds), FMRI new tower (200 beds by H1 FY27), Noida (77 beds), Manesar (~124 beds by Oct ‚Äô25).</li>
</ul></li>
</ul>
<blockquote>
<p>‚úÖ <strong>Result</strong>: Increased revenue potential, economies of scale, and asset-light O&amp;M models reducing capex load.</p>
</blockquote>
<hr />
</div>
<div id="investment-in-clinical-excellence" class="section level9">
<p class="heading">2. <strong>Investment in Clinical Excellence</strong></p>
<ul>
<li><strong>New Interventions</strong>:
<ul>
<li>Rare fetal tumor (fetus-in-fetu) removal; complex meningioma surgery.</li>
</ul></li>
<li><strong>Technology &amp; Infrastructure</strong>:
<ul>
<li><strong>Biplane Neuro Cath Lab (Mohali)</strong> ‚ûù Precision neurovascular care.</li>
<li><strong>10-bed PICU (Greater Noida)</strong> ‚ûù Pediatric ICU service expansion.</li>
</ul></li>
<li><strong>Institute of Genomic Medicine (Mohali)</strong> ‚ûù Focus on <strong>precision oncology</strong>.</li>
</ul>
<blockquote>
<p>‚úÖ Enhances <strong>brand equity, attracts high-end patients</strong>, and supports premium ARPOB.</p>
</blockquote>
<hr />
</div>
<div id="digital-access-expansion" class="section level9">
<p class="heading">3. <strong>Digital &amp; Access Expansion</strong></p>
<ul>
<li>20.4% YoY growth in digital channel revenues (website, app).</li>
<li>Multi-channel patient acquisition with improved conversion.</li>
<li>Expansion of <strong>Agilus CTPs</strong> (customer touchpoints) ensures <strong>higher diagnostic outreach</strong>.</li>
</ul>
<blockquote>
<p>üåê Strengthens patient funnel and <strong>operational efficiency</strong>.</p>
</blockquote>
<hr />
</div>
<div id="consolidation-of-agilus-diagnostics" class="section level9">
<p class="heading">4. <strong>Consolidation of Agilus Diagnostics</strong></p>
<ul>
<li>Part-financed acquisition with <strong>debt</strong>, allowing full consolidation of diagnostics EBITDA.</li>
<li>Improves group-level margins and enables vertical integration.</li>
</ul>
<blockquote>
<p>üíº High-margin, scalable diagnostics business is now fully integrated.</p>
</blockquote>
<hr />
</div>
<div id="stable-ownership-transition" class="section level9">
<p class="heading">5. <strong>Stable Ownership Transition</strong></p>
<ul>
<li>Completion of <strong>IHH‚Äôs open offer</strong> solidifies global backing, strategic control, and long-term commitment.</li>
<li>No further dilution expected; clarity on ownership structure enhances <strong>investor confidence</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-risks" class="section level6">
<h6>‚ö†Ô∏è HEADWINDS &amp; RISKS</h6>
<div id="leverage-balance-sheet-pressure" class="section level9">
<p class="heading">1. <strong>Leverage &amp; Balance Sheet Pressure</strong></p>
<ul>
<li><strong>Net Debt</strong>: INR 2,219 Cr (Sep 2025) ‚ûù up from INR 281 Cr (Sep 2024).</li>
<li><strong>Net Debt / EBITDA</strong>: <strong>0.96x</strong> (annualized Q2 FY26) ‚ûù up from <strong>0.16x</strong>.</li>
<li><strong>Net Debt / Equity</strong>: 0.23x vs 0.03x in Sep 2024.</li>
<li>Primary reason: <strong>Acquisition of Agilus stake</strong> and <strong>Jalandhar/Shrimann Hospital</strong>.</li>
</ul>
<blockquote>
<p>üö® While debt is strategic, future <strong>interest cost pressure</strong> (+INR 75 Cr in Q2 FY26 vs INR 36 Cr YoY) and refinancing risk must be monitored.</p>
</blockquote>
<hr />
</div>
<div id="dependency-on-exceptional-items" class="section level9">
<p class="heading">2. <strong>Dependency on Exceptional Items</strong></p>
<ul>
<li>PAT growth is <strong>partially inflated</strong> by exceptional gains (reversal of impairments).</li>
<li><strong>Adjusting for one-offs</strong>, underlying PAT growth is <strong>strong but lower</strong> than headline 70.3%.</li>
<li>Market may view this as <strong>non-recurring</strong>, affecting earnings quality.</li>
</ul>
<hr />
</div>
<div id="margin-pressure-from-new-facilities" class="section level9">
<p class="heading">3. <strong>Margin Pressure from New Facilities</strong></p>
<ul>
<li>Early-stage hospitals (e.g., Manesar, newly leased Greater Noida) are in <strong>&lt;10% EBITDA margin bracket</strong>, dragging system-wide averages.</li>
<li>Occupancy: As low as <strong>50‚Äì60%</strong> in some early-stage units.</li>
</ul>
<blockquote>
<p>‚è≥ Patience required ‚Äî profitability from new investments may take <strong>2‚Äì3 years</strong> to materialize.</p>
</blockquote>
<hr />
</div>
<div id="regulatory-compliance-risks" class="section level9">
<p class="heading">4. <strong>Regulatory &amp; Compliance Risks</strong></p>
<ul>
<li>Subject to SEBI LODR, SAST regulations, Ind AS compliance.</li>
<li>Healthcare sector is monitored for pricing, quality, and licensing.</li>
<li>Expansion requires <strong>health authority approvals</strong>, and delays can impact timelines.</li>
</ul>
<hr />
</div>
<div id="competition-from-apollo-max-narayana" class="section level9">
<p class="heading">5. <strong>Competition from Apollo, Max, Narayana</strong></p>
<ul>
<li>Intense competition in metros and specialty segments (oncology, cardiology).</li>
<li>Apollo Health (including Omnicare) and Max Healthcare are investing in digital, preventive, and rural expansion.</li>
<li>Fortis must <strong>differentiate on service quality, tech, and regional depth</strong>.</li>
</ul>
<hr />
</div>
<div id="fx-and-associate-related-volatility" class="section level9">
<p class="heading">6. <strong>FX and Associate-Related Volatility</strong></p>
<ul>
<li>Past earnings impacted by <strong>impairments and reversals in associate companies</strong>.</li>
<li>Ongoing exposure (e.g., RHTTM, Malar) adds volatility to <strong>P&amp;L from associates</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="payor-mix-market-position" class="section level6">
<h6>üìä Payor Mix &amp; Market Position</h6>
<ul>
<li><strong>TPA/Insurance</strong>: 36% ‚ûù growing, reduces receivables risk.</li>
<li><strong>Private Corporates</strong>: Low (~1.1%) ‚Üí room for growth.</li>
<li><strong>Wellness &amp; Preventive Care</strong>: 13% in diagnostics ‚Üí trend aligned with rising health awareness.</li>
<li>Geographic Reach: Strong in <strong>North (33%)</strong>, <strong>West (41%)</strong>, emerging in <strong>East (13%)</strong>.</li>
</ul>
<hr />
</div>
<div id="balance-sheet-cashflows" class="section level6">
<h6>üìÖ Balance Sheet &amp; Cashflows</h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Sep 30, 2025</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Total Capital Employed</strong></td>
<td>INR 12,887 Cr</td>
</tr>
<tr class="even">
<td><strong>Net Fixed Assets</strong></td>
<td>INR 7,483 Cr</td>
</tr>
<tr class="odd">
<td><strong>Goodwill</strong></td>
<td>INR 4,526 Cr ‚Üë (due to Agilus acquisition)</td>
</tr>
<tr class="even">
<td><strong>Cash &amp; Equiv.</strong></td>
<td>INR 413 Cr ‚Üì</td>
</tr>
<tr class="odd">
<td><strong>Shareholders‚Äô Equity</strong></td>
<td>INR 9,693 Cr ‚Üë</td>
</tr>
<tr class="even">
<td><strong>Lease Liabilities (Ind AS 116)</strong></td>
<td>INR 562 Cr</td>
</tr>
</tbody>
</table>
<blockquote>
<p>‚úÖ Equity growth supports leverage, but <strong>cash reserves declining</strong> with expansion.</p>
</blockquote>
<hr />
</div>
<div id="out-of-capital-investment-plan-capex-outlook" class="section level6">
<h6>üß≠ Out of Capital Investment Plan (CAPEX Outlook)</h6>
<ul>
<li>Major capital expansions underway.</li>
<li><strong>FMRI new 200-bed tower by H1 FY27</strong> ‚Äî indicates sustained CAPEX.</li>
<li>Expected to fund via hybrid instruments or internal accruals post-stabilization of new assets.</li>
</ul>
<hr />
</div>
<div id="conclusion-investment-outlook" class="section level6">
<h6>üìå Conclusion: Investment Outlook</h6>
<div id="bull-case-drivers" class="section level9">
<p class="heading">‚úÖ <strong>Bull Case Drivers</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Double-digit revenue growth</strong> in hospital and diagnostics.</li>
<li><strong>Margin expansion</strong> across segments.</li>
<li><strong>Scalable model</strong> with strong operational levers (ARPOB, volume, digital).</li>
<li><strong>Physical network expansion</strong> enhancing long-term capacity.</li>
<li><strong>Clinical and tech innovation</strong> improving brand and outcomes.</li>
<li><strong>End of ownership uncertainty</strong> post-IHH open offer.</li>
</ol>
</div>
<div id="bear-case-risks" class="section level9">
<p class="heading">üî¥ <strong>Bear Case Risks</strong></p>
<ol style="list-style-type: decimal">
<li><strong>High near-term debt</strong> burden and interest cost.</li>
<li><strong>Earnings quality</strong> concern due to one-offs.</li>
<li><strong>Time lag in profitability</strong> from new hospitals.</li>
<li><strong>Sector-wide regulatory scrutiny</strong> in pricing, quality.</li>
</ol>
</div>
<div id="outlook" class="section level9">
<p class="heading">üîÆ <strong>Outlook</strong></p>
<p>Fortis is at an <strong>inflection point</strong>: - Transitioning from <strong>ownership-led uncertainty</strong> to <strong>execution-driven growth</strong>. - <strong>Hospital business is recovering</strong>, diagnostics is scaling, and margins are improving. - FY26 and FY27 likely to be <strong>investment years</strong>, with <strong>FY28 onwards seeing higher free cash flow conversion</strong>.</p>
<hr />
</div>
</div>
<div id="recommendation-summary-for-investors" class="section level6">
<h6>üíé Recommendation Summary (for Investors)</h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Category</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Momentum</strong></td>
<td>Strong: driven by volume, ARPOB, specialty care</td>
</tr>
<tr class="even">
<td><strong>Margins</strong></td>
<td>Improving: EBITDA margin up 200 bps YoY</td>
</tr>
<tr class="odd">
<td><strong>Balance Sheet</strong></td>
<td>Weaker short-term: elevated net debt, but strategic capex</td>
</tr>
<tr class="even">
<td><strong>Ownership Clarity</strong></td>
<td>Excellent: IHH consolidation complete</td>
</tr>
<tr class="odd">
<td><strong>Strategic Outlook</strong></td>
<td>Positive: expanding in growth corridors (NCR, Punjab, Lucknow)</td>
</tr>
<tr class="even">
<td><strong>Valuation Watchpoint</strong></td>
<td>Margins must stabilize and debt must deleverage over H2 FY26‚ÄìFY27</td>
</tr>
<tr class="odd">
<td><strong>Risks</strong></td>
<td>Moderately High: CAPEX cycle, interest costs, margin volatility</td>
</tr>
</tbody>
</table>
<hr />
<div id="final-verdict" class="section level9">
<p class="heading">üîö <strong>Final Verdict</strong></p>
<p><strong>Hold / Buy-on-dips for medium-to-long-term</strong>:<br />
Fortis is <strong>executing well</strong> on growth and integration under IHH. Despite <strong>near-term financial headwinds</strong>, the business is moving towards <strong>sustainable profitability</strong>, supported by <strong>clinical excellence, operational efficiency, and network expansion</strong>. Investors should monitor <strong>debt reduction</strong>, <strong>ROCE improvement</strong>, and <strong>occupancy stabilization</strong> in new facilities for higher conviction.</p>
<hr />
<p>üì¨ <strong>For IR/Analyst Contact</strong>: - <strong>Anurag Kalra / Amit Mahendru (Investor Relations)</strong>: +91-9810109253 / +91-9891094323<br />
- <strong>Ajey Maharaj (Corporate Comm.)</strong>: +91-9871798573<br />
- Email: <a href="mailto:secretarial@fortishealthcare.com" class="email">secretarial@fortishealthcare.com</a></p>
<blockquote>
<p><em>Forward-Looking Disclaimer as per SEBI norms applies. This analysis is based on disclosed information as of Nov 11, 2025.</em></p>
</blockquote>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
